STAAR Surgical Company STAA R2KR3KPHARMA
Company Overview
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Why Investors Should Care
Revenue has grown at a 10.1% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.10.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Jan 2026 Revenue of $239.44M (-23.7% YoY); net profit $-80.45M.
- Trailing 12 Months Year-on-year growth — revenue +111.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 10.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 10.14% |
| 1 Year: | 111.00% |
Stock Price Performance
| 1 Year: | -19.85% |
| 6 Months: | -11.92% |
| 3 Months: | -1.48% |
| 1 Month: | +18.50% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)53.69 · Neutral
P/E of 282.62 is above the sector median of 25.45 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 10.1% over 5 years.
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 282.6.
- Trading 32.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | STAA STAAR Surgical Company R2KR3KPHARMA | 22.61 | 282.62 | $1.13B | 0.00% | -23.94% | 1.09% | 10.14% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jul 2015 | Oct 2015 | Jan 2016 | Apr 2016 | Jul 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Jan 2020 | Apr 2020 | Jul 2020 | Oct 2020 | Jan 2021 | Apr 2021 | Jul 2021 | Oct 2021 | Dec 2021 | Apr 2022 | Jul 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 5.93M | 6.61M | 5.35M | - | 4.80M | 5.23M | 5.24M | - | 5.85M | 4.47M | 5.59M | - | 4.25M | 3.13M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 12.36M | 12.80M | 14.66M | 12.99M | 14.63M | 14.87M | 15.88M | 14.58M | 15.47M | 16.85M | 17.38M | 19.43M | 25.23M | 23.86M | 22.99M | 24.18M | 29.90M | 29.05M | 28.82M | 24.76M | 24.43M | 34.87M | 34.30M | 39.14M | 49.20M | 45.30M | 44.99M | 49.26M | 63.87M | 60.46M | 57.56M | 70.73M | 63.64M | 61.03M | 78.41M | 68.49M | 28.00M | 32.80M | 77.88M | 68.86M |
| Operating Income | -1.74M | -2.02M | - | -10.05M | -2.14M | -1.72M | - | -2.08M | -1.32M | 1.04M | - | 799.00K | 3.03M | 1.58M | - | 1.56M | 4.61M | 3.33M | - | -1.14M | -1.05M | 4.88M | - | 7.47M | 10.65M | 7.84M | - | 12.11M | 17.02M | 13.71M | 2.80M | 8.60M | 6.29M | -2.28M | 11.90M | 5.68M | -57.40M | -29.96M | 18.49M | 7.98M |
| Net Income | -1.60M | -1.75M | -842.00K | -8.04M | -2.14M | -1.78M | -167.00K | -2.20M | -971.00K | 1.17M | -138.00K | 583.00K | 1.83M | 1.46M | 1.10M | 1.37M | 3.91M | 2.39M | 6.38M | -134.00K | -1.17M | 3.89M | 3.33M | 4.99M | 8.57M | 6.02M | 4.92M | 9.60M | 13.04M | 10.26M | 2.71M | 6.06M | 4.82M | -3.34M | 7.38M | 9.98M | -54.21M | -16.81M | 8.88M | 5.21M |
| Diluted EPS | - | - | - | - | - | -0.04 | - | -0.05 | -0.02 | 0.03 | - | 0.01 | 0.04 | 0.03 | 0.02 | 0.03 | 0.08 | 0.05 | 0.14 | 0.00 | -0.03 | 0.08 | 0.07 | 0.10 | 0.17 | 0.12 | 0.10 | 0.19 | 0.26 | 0.21 | 0.05 | 0.12 | 0.10 | -0.07 | 0.15 | 0.20 | -1.10 | -0.34 | 0.18 | 0.10 |
| R&D Expense | 3.54M | 3.68M | - | 6.91M | 4.66M | 4.45M | - | 4.78M | 4.77M | 4.59M | - | 5.41M | 5.35M | 5.57M | - | 5.63M | 6.10M | 6.16M | - | 6.90M | 7.31M | 8.75M | - | 8.26M | 8.26M | 8.27M | - | 7.94M | 8.64M | 9.62M | 10.31M | 11.76M | 11.47M | 13.38M | 11.87M | 12.25M | 11.34M | 10.26M | 9.21M | 9.93M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jan 2010 | Dec 2010 | Dec 2011 | Dec 2012 | Jan 2014 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Jan 2020 | Jan 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 51.06M | 54.96M | 62.77M | 63.78M | 72.22M | 74.99M | 77.12M | 23.32M | 22.29M | 22.87M | 20.86M | 22.05M | 230.47M | 239.44M | 322.42M | 313.90M | 239.44M |
| Gross Profit | 31.32M | 35.08M | 42.37M | 44.29M | 50.31M | 48.82M | 52.72M | 58.37M | 64.28M | 91.51M | 111.95M | 118.36M | 178.64M | 223.38M | 252.65M | 239.58M | 182.42M |
| Operating Income | -4.88M | -2.60M | 2.78M | -1.22M | 700.00K | -8.03M | -5.34M | -12.65M | -3.63M | 6.59M | 11.85M | 6.77M | 33.34M | 43.80M | 28.10M | -12.61M | -91.71M |
| Net Income | -6.20M | 53.00K | 1.35M | -1.76M | 398.00K | -8.39M | -6.53M | -12.13M | -2.14M | 4.97M | 14.05M | 5.91M | 27.51M | 39.66M | 21.35M | -20.21M | -80.45M |
| Diluted EPS | -0.19 | 0.00 | 0.04 | -0.05 | 0.01 | -0.22 | -0.17 | -0.30 | -0.05 | 0.11 | 0.30 | 0.12 | 0.56 | 0.80 | 0.43 | -0.41 | -1.62 |
| R&D Expense | 5.89M | 5.72M | 5.87M | 6.44M | 6.71M | 12.36M | 14.76M | 20.67M | 20.04M | 22.03M | 25.30M | 31.92M | 33.86M | 35.98M | 40.48M | 45.32M | 40.05M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jan 2009 | Dec 2009 | Jan 2010 | Dec 2010 | Dec 2011 | Dec 2012 | Jan 2014 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Jan 2020 | Jan 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 40.59M | 49.01M | 54.76M | 61.93M | 58.91M | 62.95M | 65.48M | 67.93M | 167.34M | 207.52M | 257.42M | 345.78M | 418.82M | 488.69M | 509.52M | 451.68M |
| Total Equity | 16.03M | 21.07M | 21.07M | 22.43M | 29.46M | 31.74M | 38.85M | 37.10M | 38.85M | 37.91M | 42.94M | 132.43M | 159.88M | 197.22M | 261.57M | 336.11M | 385.95M | 397.33M | 344.18M |
| Cash & Equivalents | 4.99M | 6.33M | 6.33M | 9.38M | 16.58M | 21.68M | 22.95M | 13.01M | 13.40M | 14.00M | 18.52M | 103.88M | 119.97M | 152.45M | 199.71M | 86.48M | 183.04M | 144.16M | 153.15M |
| Total Liabilities | - | - | - | 18.16M | 19.55M | 23.02M | 23.08M | 21.81M | 24.11M | 27.57M | 25.00M | 34.91M | 47.64M | 60.19M | 87.22M | 82.71M | 102.74M | 112.19M | 107.49M |
| Current Liabilities | - | - | - | 13.45M | 14.02M | 17.95M | 18.41M | 16.37M | 17.89M | 21.07M | 19.09M | 27.73M | 34.48M | 41.24M | 48.80M | 51.72M | 65.04M | 70.31M | 68.50M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jan 2010 | Dec 2010 | Dec 2011 | Dec 2012 | Jan 2014 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Jan 2020 | Jan 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 1.43M | -4.42M | 5.35M | 3.22M | - | - | -2.16M | 1.05M | 2.85M | 12.77M | 25.80M | 20.95M | 43.96M | 35.72M | 14.59M | 15.72M | -34.23M |
| Investing Cash Flow | -7.61M | 18.77M | -889.00K | -2.15M | - | - | -2.04M | -3.21M | -1.05M | -2.25M | -10.18M | -8.40M | -13.64M | -156.38M | 74.35M | -59.22M | 46.34M |
| Financing Cash Flow | 7.36M | -11.52M | 2.77M | 4.28M | - | - | 4.58M | 2.95M | 2.44M | 74.64M | 149.00K | 19.57M | 17.79M | 8.30M | 7.42M | 5.72M | -4.55M |
| Capital Expenditure | -553.00K | -320.00K | -962.00K | -2.27M | -3.45M | -4.05M | -2.04M | -3.21M | -1.05M | -2.25M | -10.10M | -8.40M | -13.64M | -18.11M | -18.19M | -23.39M | -5.82M |
| Free Cash Flow | 874.00K | -4.74M | 4.38M | 946.00K | - | - | -4.21M | -2.16M | 1.81M | 10.52M | 15.70M | 12.55M | 30.32M | 17.61M | -3.59M | -7.67M | -40.05M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.46M |
Ratios (Annual)
Figures in %.
| Metric | Jan 2010 | Dec 2010 | Dec 2011 | Dec 2012 | Jan 2014 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Jan 2020 | Jan 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 61.3% | 63.8% | 67.5% | 69.4% | 69.7% | 65.1% | 68.4% | 250.3% | 288.4% | 400.1% | 536.6% | 536.7% | 77.5% | 93.3% | 78.4% | 76.3% | 76.2% |
| Operating Margin % | -9.6% | -4.7% | 4.4% | -1.9% | 1.0% | -10.7% | -6.9% | -54.3% | -16.3% | 28.8% | 56.8% | 30.7% | 14.5% | 18.3% | 8.7% | -4.0% | -38.3% |
| Net Margin % | -12.1% | 0.1% | 2.1% | -2.8% | 0.6% | -11.2% | -8.5% | -52.0% | -9.6% | 21.7% | 67.3% | 26.8% | 11.9% | 16.6% | 6.6% | -6.4% | -33.6% |
| ROE % | -29.4% | 0.2% | 4.6% | -5.6% | 1.0% | -22.6% | -16.8% | -32.0% | -5.0% | 3.8% | 8.8% | 3.0% | 10.5% | 11.8% | 5.5% | -5.1% | -23.4% |
| ROCE % | - | -9.6% | 8.0% | -3.3% | 1.6% | -18.9% | -11.8% | -28.5% | -7.4% | 4.7% | 6.8% | 3.1% | 11.2% | 11.9% | 6.6% | -2.9% | -23.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Broadwood Capital, Inc. | 32.16% | 16.12M | $349.40M |
| 2 | Blackrock Inc. | 13.42% | 6.73M | $145.86M |
| 3 | Madison Avenue Partners, LP | 8.33% | 4.18M | $90.49M |
| 4 | Yunqi Capital Ltd | 6.50% | 3.26M | $70.58M |
| 5 | Point72 Asset Management, L.P. | 4.86% | 2.44M | $52.82M |
| 6 | Goldman Sachs Group Inc | 4.29% | 2.15M | $46.61M |
| 7 | Vanguard Portfolio Management LLC | 3.95% | 1.98M | $42.90M |
| 8 | State Street Corporation | 3.53% | 1.77M | $38.34M |
| 9 | Anatole Investment Management Ltd | 3.29% | 1.65M | $35.79M |
| 10 | Vanguard Capital Management LLC | 3.10% | 1.55M | $33.65M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for STAA
STAAR Surgical Company (STAA) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE55WGJkempEajc5WUhUNGFoQldXSFA0S3BRT3BJZUJYWWh3WHFUVzA0SzJqWWRrVW83ZVlSSFU3V3NaYVdWeDIwbjFKOWRzWEZmdkE?oc=5" target="_blank">STAAR Surgical Company (STAA) stock price, news, quote a…
Staar Surgical(STAA) Stock Options Chain | Quotes & News - Moomoo
<a href="https://news.google.com/rss/articles/CBMiiwNBVV95cUxNdFlxOHBqMy1xYzNHS1hrUXdMZldfekkwN3VRRWsyWGxDbHJZY2J3Nmc4XzRLTHczOUs1dUpIUVRZV1E4T3ZUeFRNdENGWXg0bTZ5aURZd0piUG5mNUlkcThCelhOWExHOTluV0lucDM3WEVEazJrVmJhQWtnT05MdmRJeEEwTk9VWF9ROE…
STAAR Surgical Company (STAA) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE1ha2JRMTRSN3pDY3ExS0xEWl9lQWtaMFlka1RDQnZMcFlMdFVjalZjOTF1RWREZjVaQWpKUGhTRkF2LWVVQ3Y5Z29yb3dlVWZUZnc?oc=5" target="_blank">STAAR Surgical Company (STAA) Stock Price, News, Quote &…
Third-quarter results from STAAR Surgical are scheduled for release after markets close Nov. 4. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQLU1KV2F1N25YdC1fTDU3dEVUWTBvRzd0d1E5LVZwc2VqT2NvN2thVWhXNnRHT2hnc2N5TVlQWGMxWXlJanBwaWVtc2ZKa0VSbEJmSTl6WU1TWTRYTnJfaDdOSEhEbXI3QkpDbGVWS3dpRFVPOXI1ZXVORWxNM1RMaElYM01pZUpNVmdWem…
STAAR Surgical (STAA) Stock Could Be Cheap As Shares Fell 82% - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPRUhyQnBuVDk3VlRiT0Myb0QyVGxndk9iSGJvd3JTSGxRQU5VOHZCd0Nxc2tyRFdCUTlqYzN6R0FCR3JaTkFEWkU1ckdyeGJadzJ3eERzUHdDNUlsXzVaMVlORkJXTVFfM2Q2QjJWVndFcDhCOTJTNERaR1JnUjRlUm40YXdrYnd0Yy0wM0…
STAA Stock On Track For Its Fourth Straight Session Of Gains – This Analyst Would Rather Be Early Than Late On Staar’s Growth Story - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxQTFRXaVpwb3U5bG1zLUxRTGZxQXFCZ1RiSmlHaUU3S196LTN2Mkd6RjJHcWVONWpJUEd2U01CQk9JUXYybHRkVktzY2JQN1lFaUc1X04tTlFTZ3dKMXctdEdJYWpPTEJOUnlSZVR0Mk9fUjRMUU40LWdjQUMxaktHM0FXZVZSdjVDcS1HZX…
STAA — Frequently Asked Questions
What is the current share price of STAAR Surgical Company (STAA)?
As of 2026-10-23 16:27 PDT, STAAR Surgical Company (STAA) trades at $22.61 on NasdaqGM. Its 52-week range is $16.10 to $33.34.
What is the market capitalisation of STAA?
STAAR Surgical Company (STAA) has a market capitalisation of $1.13B on NasdaqGM.
What is the P/E ratio of STAA?
STAA trades at a trailing price-to-earnings (P/E) ratio of 282.62. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 2.86.
What is the return on equity (ROE) of STAA?
STAA has a return on equity (ROE) of 1.09%. Its return on capital employed (ROCE) is -23.94%.
Is STAA a good stock to buy?
This page provides a data-driven analysis of STAAR Surgical Company (STAA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.